Industry News

Bionor Pharma ASA regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue."/>
Bionor Pharma ASA : Primary inside Notification - Jens Krøis
Bionor Pharma ASA regarding the primary insider notification from certain primary insiders of the Company that have received Subscription Rights in the Rights Issue."/>
Bionor Pharma ASA : Primary inside Notification - Per S. Thoresen
BIONOR PHARMA ASA STOCK EXCHANGE ANNOUNCEMENT NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG OR THE UNITED STATES Bionor Pharma- Expiry of subscription period and last day of trading in subscription rights today Reference is made to previous stock exchange announcements and the prospectus dated 14 September 2016 concerning the rights issue of 525,000,000 new shares at a subscription price of NOK..."/>
Bionor Pharma - Expiry of subscription period and last day of trading in subscription rights today
Galapagos NV and MorphoSys AG announced today that the first patient with atopic..."/>
MorphoSys and Galapagos Start First-In-Patient Dosing of IL-17C Antibody MOR106 in Atopic Dermatitis
Sun Pharmaceutical Industries Ltd against an order of the Maharashtra Industrial Court asking the company to pay pending wages of 86 sales representatives who joined the company after its merger with Ranbaxy Laboratories Ltd.. The Federation of Medical and Sales Representatives' Associations of India had filed a lawsuit against Sun Pharma in June, alleging that the company was engaging in..."/>
BRIEF: Bombay HC orders Sun Pharma to cough up pending wages [Mint, New Delhi]
Medtronic PLC's MiniMed 670 G "hybrid closed-loop" system received approval from the FDA just three months after the Minnesota-run device maker submitted its premarket..."/>
Medtronic gets FDA approval for automated insulin delivery device [Star Tribune (Minneapolis)]
Agilent Technologies Inc. and Burning Rock today announced they have signed an agreement under which Burning Rock will develop cancer diagnostics in China based on the Agilent SureSelect target enrichment system. Agilent is the leading provider of target enrichment for next-generation DNA sequencing."/>
Agilent Technologies and Burning Rock Sign Agreement on Molecular Diagnostics
Avita Medical's regenerative medical devices will soon open in Iran following the appointment of an exclusive distributor in this significant aesthetic market, the Company, said today. Avita Medical Ltd, a regenerative medicine company specialising in new treatments for wounds and skin defects, said the clinic in Tehran would in the first instance treat patients for..."/>
Avita Medical Signs Exclusive Distributor Deal in Iran
AbbVie, a global biopharmaceutical company, today strengthened its manufacturing capabilities by opening the small molecule active pharmaceutical ingredient facility of its Singapore manufacturing site. This facility supports the growth of AbbVie's oncology and women's health pipeline and reflects progress from AbbVie's two previous announcements for manufacturing investment in Asia in 2014.. The new 120,000 square-meter site–..."/>
AbbVie Opens First Phase of its Global Manufacturing Facility in Singapore to Support the Growth of its Pipeline
Alcobra Ltd., an emerging pharmaceutical company focused on the development of new medications to treat patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder and Fragile X Syndrome, today announced that it has received verbal notice from the Division of Psychiatry Products of the U.S. Food and Drug Administration that a full clinical hold has been placed on its Investigational New Drug applications for MDX in..."/>
Alcobra Announces IND Clinical Hold Affecting the MDX Phase III MEASURE Study
Cynapsus Therapeutics Inc. is pleased to announce today that Institutional Shareholder Services, a leading independent proxy advisory firm, has recommended that Cynapsus shareholders and warrantholders vote FOR the special resolution to approve the previously announced plan of arrangement whereby Sunovion CNS Development Canada ULC, a wholly owned subsidiary of Sunovion Pharmaceuticals Inc., will acquire all of the outstanding common shares..."/>
ISS Recommends Cynapsus Therapeutics Securityholders Vote for the Plan of Arrangement
Apricus Biosciences, Inc., a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that it has closed a registered direct offering of shares of common stock with institutional investors for gross proceeds of approximately $3.7 million. Based on feedback from the Nasdaq stock market, Apricus and the investors mutually agreed to revise the size of the offering such that fewer shares of common stock were..."/>
Apricus Biosciences Closes $3.7 Million Registered Direct Offering
Tabula Rasa HealthCare, Inc., a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk, today announced the pricing of its initial public offering of 4,300,000 shares of its common stock, at a price of $12.00 per share, before underwriting discounts and..."/>
Tabula Rasa HealthCare Announces Pricing of Initial Public Offering
Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, today announced the first patient dosed in the phase III clinical trial of SRP-4045 and SRP-4053 in patients with Duchenne muscular dystrophy amenable to exon 45 or 53 skipping. “We are excited to announce the first patient dosed in our ESSENCE trial of SRP-4045 and SRP-4053, for DMD patients amenable to Exon 45 and 53 skipping“ said Edward Kaye, Sarepta’ s chief executive officer.“..."/>
Sarepta Therapeutics Announces First Patient Dosed in Phase III Clinical Trial of SRP-4045 and SRP-4053 for the Treatment of Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping
Pfizer Inc. closed the acquisition of small molecule biopharmaceutical company Medivation, Inc. in a merger valued at for USD 81.50 a share in cash for a total enterprise value of approximately USD 14 bn, the company said. The boards of directors of both companies have unanimously approved the merger, which is expected to be immediately accretive to Pfizer's adjusted diluted EPS upon closing. Pfizer does not expect..."/>
Pfizer Closes USD 14bn Acquisition of Drugmaker Medivation
CareDx, Inc., a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, announced the launch of Olerup QTYPE ® at the 42 nd Annual Meeting of the American Society of Histocompatability and Immunogenetics in St. During a lunchtime symposium on the pre-to-post transplant continuum, John Lunz, PhD, from the Gift of Hope Organ..."/>
CareDx Launches Olerup QTYPE® at ASHI  
Cigna by Anthem would hurt competition in the individual health insurance market on Obamacare's exchanges. The antitrust regulators sued in July to stop the deal and another in which Hartford-based Aetna would purchase Humana, arguing that limited health care competition would increase costs for consumers, doctors and hospitals."/>
Justice Department Modifies Anthem-Cigna Lawsuit [The Hartford Courant]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology712 Articles
Consumer Discretionary595 Articles
Financials445 Articles
Industrials390 Articles
Health Care385 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.